ILIAS Biologics has obtained approval from Australia’s Human Research Ethics Committee (HREC) to commence the first-in-human Phase I clinical trial of ILB-202 to treat cardiac surgery-associated acute kidney injury (CSA-AKI).

Developed using the company’s EXPLOR platform, ILB-202 is an exosome therapy and contains anti-inflammatory protein super-repressor lκB (srlκB).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is intended to weaken inflammatory responses in several disease models by introducing srlκB to hinder NF-κB translocation into the nucleus. 

ILIAS is claimed to be the first Korean firm to advance exosome-based therapeutics to global trial. 

This trial will assess the safety and tolerability of ILB-202 in healthy adult subjects.

ILIAS Biologics co-CEO Chulhee Choi said: “With the approval to initiate the first-in-human clinical trial of ILB 202, we are one step closer to developing novel exosome-based therapeutics to help patients in need. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“ILIAS has proven the efficacy of ILB-202 in multiple inflammation-related therapeutic areas via proof-of-concept studies. 

“Starting with AKI, we plan to expand the indications of ILB-202 and look forward to providing millions of patients suffering from inflammatory diseases with an effective new treatment.”

The therapeutic efficacy of the company’s anti-inflammatory exosomes to treat ischemia reperfusion injury-AKI (IRI-AKI) was demonstrated earlier. 

Furthermore, the systemic administration of anti-inflammatory exosomes into preclinical IRI-AKI mouse models showed to substantially reduce AKI-associated biomarker levels in the blood, i.e., blood urea nitrogen, creatine and neutrophil gelatinase-associated lipocalin.

Currently, there exists no approved drug that offers clear therapeutic benefits for AKI, which is characterised by a fast reduction in kidney function. It can be caused by a variety of conditions, such as acute tubular necrosis and interstitial nephritis.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact